Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Genetic Predisposition to Symptomatic Lumbar Disk Herniation in Pediatric and Young Adult Patients.

Theodore N, Ahmed AK, Fulton T, Mousses S, Yoo C, Goodwin CR, Danielson J, Sciubba DM, Giers MB, Kalani MYS.

Spine (Phila Pa 1976). 2019 Jun 1;44(11):E640-E649. doi: 10.1097/BRS.0000000000002949.

PMID:
30475332
2.

Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer.

Tüzmen Ş, Hostetter G, Watanabe A, Ekmekçi C, Carrigan PE, Shechter I, Kallioniemi O, Miller LJ, Mousses S.

Per Med. 2019 Jan;16(1):51-65. doi: 10.2217/pme-2016-0058. Epub 2018 Nov 23.

PMID:
30468409
3.

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.

Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD.

Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.

4.

The BioIntelligence Framework: a new computational platform for biomedical knowledge computing.

Farley T, Kiefer J, Lee P, Von Hoff D, Trent JM, Colbourn C, Mousses S.

J Am Med Inform Assoc. 2013 Jan 1;20(1):128-33. doi: 10.1136/amiajnl-2011-000646. Epub 2012 Aug 2.

5.

Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.

Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H, Mousses S, Stewart AK.

Cancer Res. 2012 Feb 1;72(3):757-68. doi: 10.1158/0008-5472.CAN-11-2781. Epub 2011 Dec 6.

6.

Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.

Xie L, Kassner M, Munoz RM, Que QQ, Kiefer J, Zhao Y, Mousses S, Yin HH, Von Hoff DD, Han H.

Biochem Pharmacol. 2012 Feb 15;83(4):452-61. doi: 10.1016/j.bcp.2011.11.005. Epub 2011 Nov 15.

7.

An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer.

Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E, Malcolm K, Mousses S, Tonin PN, Basik M.

Oncogene. 2012 Apr 19;31(16):2090-100. doi: 10.1038/onc.2011.386. Epub 2011 Sep 5.

PMID:
21892209
8.

Advancing a clinically relevant perspective of the clonal nature of cancer.

Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, Rabinovitch PS, Zellweger T, Mousses S, Trent JM, Carpten JD, Bubendorf L, Von Hoff D, Barrett MT.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12054-9. doi: 10.1073/pnas.1104009108. Epub 2011 Jul 5.

9.

High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.

Henderson MC, Gonzales IM, Arora S, Choudhary A, Trent JM, Von Hoff DD, Mousses S, Azorsa DO.

Mol Cancer Res. 2011 Jun;9(6):724-32. doi: 10.1158/1541-7786.MCR-10-0436. Epub 2011 May 2.

10.

Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.

Ruiz C, Holz DR, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin HJ, Mousses S, Barrett MT, Azorsa DO, Bubendorf L.

J Pathol. 2011 Mar;223(4):543-52. doi: 10.1002/path.2828. Epub 2011 Jan 5.

PMID:
21294127
11.

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S, Stewart AK.

Blood. 2011 Apr 7;117(14):3847-57. doi: 10.1182/blood-2010-08-304022. Epub 2011 Feb 2.

12.

RNAi-based functional pharmacogenomics.

Tuzmen S, Tuzmen P, Arora S, Mousses S, Azorsa D.

Methods Mol Biol. 2011;700:271-90. doi: 10.1007/978-1-61737-954-3_18.

PMID:
21204040
13.

Elevated expression of the cytochrome b561, a neuroendocrine vesicle protein, in castration resistant prostate tumors.

Srivastava A, Mousses S, Dobi A, Leighton X.

Cancer Biomark. 2010;7(1):17-23. doi: 10.3233/CBM-2010-0142.

PMID:
21045261
14.

RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.

Arora S, Gonzales IM, Hagelstrom RT, Beaudry C, Choudhary A, Sima C, Tibes R, Mousses S, Azorsa DO.

Mol Cancer. 2010 Aug 18;9:218. doi: 10.1186/1476-4598-9-218.

15.

Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.

Wolf M, Korja M, Karhu R, Edgren H, Kilpinen S, Ojala K, Mousses S, Kallioniemi A, Haapasalo H.

BMC Cancer. 2010 May 5;10:181. doi: 10.1186/1471-2407-10-181.

16.

Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.

Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW Jr, Badve S.

Breast Cancer Res Treat. 2010 Nov;124(2):327-35. doi: 10.1007/s10549-010-0733-2. Epub 2010 Jan 23.

PMID:
20099025
17.

High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation.

Azorsa DO, Robeson RH, Frost D, Meec hoovet B, Brautigam GR, Dickey C, Beaudry C, Basu GD, Holz DR, Hernandez JA, Bisanz KM, Gwinn L, Grover A, Rogers J, Reiman EM, Hutton M, Stephan DA, Mousses S, Dunckley T.

BMC Genomics. 2010 Jan 12;11:25. doi: 10.1186/1471-2164-11-25.

18.

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.

Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S, Stewart AK.

Blood. 2010 Feb 25;115(8):1594-604. doi: 10.1182/blood-2009-09-243980. Epub 2009 Dec 7.

19.

Using biointelligence to search the cancer genome: an epistemological perspective on knowledge recovery strategies to enable precision medical genomics.

Mousses S, Kiefer J, Von Hoff D, Trent J.

Oncogene. 2008 Dec;27 Suppl 2:S58-66. doi: 10.1038/onc.2009.354. Review.

PMID:
19956181
20.

High-throughput siRNA screening as a method of perturbation of biological systems and identification of targeted pathways coupled with compound screening.

Kiefer J, Yin HH, Que QQ, Mousses S.

Methods Mol Biol. 2009;563:275-87. doi: 10.1007/978-1-60761-175-2_15.

PMID:
19597791
21.

Pancreatic cancer--could it be that simple? A different context of vulnerability.

Von Hoff DD, Korn R, Mousses S.

Cancer Cell. 2009 Jul 7;16(1):7-8. doi: 10.1016/j.ccr.2009.06.011.

22.

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S.

J Transl Med. 2009 Jun 11;7:43. doi: 10.1186/1479-5876-7-43.

23.

Functional evidence implicating S100P in prostate cancer progression.

Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S.

Int J Cancer. 2008 Jul 15;123(2):330-339. doi: 10.1002/ijc.23447.

24.

Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine.

Jarjanazi H, Kiefer J, Savas S, Briollais L, Tuzmen S, Pabalan N, Ibrahim-Zada I, Mousses S, Ozcelik H.

Hum Mutat. 2008 Apr;29(4):461-7. doi: 10.1002/humu.20732.

PMID:
18330920
25.

PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation.

Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T, Carpten JD.

Br J Haematol. 2008 Feb;140(3):344-7. Epub 2007 Dec 5.

26.

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.

Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE.

Nature. 2007 Jul 26;448(7152):439-44. Epub 2007 Jul 4.

PMID:
17611497
27.

Validation of short interfering RNA knockdowns by quantitative real-time PCR.

Tuzmen S, Kiefer J, Mousses S.

Methods Mol Biol. 2007;353:177-203.

PMID:
17332642
28.

Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification.

Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, Mousses S, Kallioniemi A.

Cancer Res. 2007 Mar 1;67(5):1943-9.

29.

Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.

Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, Wang R, Konaka H, Nakagawa M, Mousses S, Amin M, Anderson C, Johnstone P, Petros JA, Marshall FF, Zhau HE, Chung LW.

Cancer Res. 2006 Oct 1;66(19):9519-26.

30.

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.

Wang H, Han H, Mousses S, Von Hoff DD.

Semin Oncol. 2006 Aug;33(4):513-20. Review.

PMID:
16890805
31.

Identification of molecular markers for endometriosis in blood lymphocytes by using deoxyribonucleic acid microarrays.

Flores I, Rivera E, Mousses S, Chen Y, Rozenblum E.

Fertil Steril. 2006 Jun;85(6):1676-83.

PMID:
16759924
32.

EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers.

Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G, Kallioniemi OP, Mousses S, Tornillo L.

Clin Cancer Res. 2005 Sep 15;11(18):6450-8.

33.

A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history.

Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, Huusko P, Pettaway C, Vijayakumar S, Bennett J, Hoke G, Mason T, Weinrich S, Trent JM, Collins FS, Mousses S, Bailey-Wilson J, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD.

J Med Genet. 2006 Jun;43(6):507-11. Epub 2005 Sep 9.

34.

NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer.

Wolf M, Edgren H, Muggerud A, Kilpinen S, Huusko P, Sørlie T, Mousses S, Kallioniemi O.

Cell Oncol. 2005;27(3):169-73. Review.

35.

Genome scale cytometry: High content analysis for high throughput RNAi phenotype profiling.

Evans DM, Azorsa DO, Mousses S.

Drug Discov Today Technol. 2005 Summer;2(2):141-7. doi: 10.1016/j.ddtec.2005.05.012.

PMID:
24981841
36.

Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer.

Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, Elkahloun A, Basik M, Bova GS, Bubendorf L, Lugli A, Sauter G, Schleutker J, Ozcelik H, Elowe S, Pawson T, Trent JM, Carpten JD, Kallioniemi OP, Mousses S.

Nat Genet. 2004 Sep;36(9):979-83. Epub 2004 Aug 8.

PMID:
15300251
37.

High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression.

Wolf M, Mousses S, Hautaniemi S, Karhu R, Huusko P, Allinen M, Elkahloun A, Monni O, Chen Y, Kallioniemi A, Kallioniemi OP.

Neoplasia. 2004 May-Jun;6(3):240-7.

38.

Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells.

Caplen NJ, Mousses S.

Ann N Y Acad Sci. 2003 Dec;1002:56-62. Review.

PMID:
14751822
39.

Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome.

Skotheim RI, Kallioniemi A, Bjerkhagen B, Mertens F, Brekke HR, Monni O, Mousses S, Mandahl N, Soeter G, Nesland JM, Smeland S, Kallioniemi OP, Lothe RA.

J Clin Oncol. 2003 Dec 15;21(24):4586-91. Erratum in: J Clin Oncol. 2004 Mar 1;22(5):969.

PMID:
14673046
40.

RNAi microarray analysis in cultured mammalian cells.

Mousses S, Caplen NJ, Cornelison R, Weaver D, Basik M, Hautaniemi S, Elkahloun AG, Lotufo RA, Choudary A, Dougherty ER, Suh E, Kallioniemi O.

Genome Res. 2003 Oct;13(10):2341-7.

41.

Integration of genomic technologies for accelerated cancer drug development.

Basik M, Mousses S, Trent J.

Biotechniques. 2003 Sep;35(3):580-2, 584, 586 passim. Review.

42.

Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.

Eder IE, Haag P, Basik M, Mousses S, Bektic J, Bartsch G, Klocker H.

Mol Carcinog. 2003 Aug;37(4):181-91.

PMID:
12891627
43.

Harnessing the power of RNA interference to advance anticancer drug development.

Mousses S.

Mol Cancer Ther. 2003 Mar;2(3):217-8. No abstract available.

44.

Impact of DNA amplification on gene expression patterns in breast cancer.

Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringnér M, Sauter G, Monni O, Elkahloun A, Kallioniemi OP, Kallioniemi A.

Cancer Res. 2002 Nov 1;62(21):6240-5.

45.

New insights into testicular germ cell tumorigenesis from gene expression profiling.

Skotheim RI, Monni O, Mousses S, Fosså SD, Kallioniemi OP, Lothe RA, Kallioniemi A.

Cancer Res. 2002 Apr 15;62(8):2359-64.

46.

Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays.

Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cornelison R, Goldberger N, Elkahloun AG, Willi N, Koivisto P, Ferhle W, Raffeld M, Sauter G, Kallioniemi OP.

Cancer Res. 2002 Mar 1;62(5):1256-60.

47.

Clinical and functional target validation using tissue and cell microarrays.

Mousses S, Kallioniemi A, Kauraniemi P, Elkahloun A, Kallioniemi OP.

Curr Opin Chem Biol. 2002 Feb;6(1):97-101. Review.

PMID:
11827831
48.

Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling.

Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB, Kallioniemi OP.

Oncogene. 2001 Oct 11;20(46):6718-23.

49.

Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma.

Gokgoz N, Wunder JS, Mousses S, Eskandarian S, Bell RS, Andrulis IL.

Cancer. 2001 Oct 15;92(8):2181-9.

PMID:
11596036
50.

From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome.

Monni O, Hyman E, Mousses S, Barlund M, Kallioniemi A, Kallioniemi OP.

Semin Cancer Biol. 2001 Oct;11(5):395-401. Review.

PMID:
11562182

Supplemental Content

Loading ...
Support Center